209 related articles for article (PubMed ID: 15932386)
1. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.
Simon D; Vassina E; Yousefi S; Braathen LR; Simon HU
Allergy; 2005 Jul; 60(7):944-51. PubMed ID: 15932386
[TBL] [Abstract][Full Text] [Related]
2. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
Simon D; Vassina E; Yousefi S; Kozlowski E; Braathen LR; Simon HU
J Allergy Clin Immunol; 2004 Oct; 114(4):887-95. PubMed ID: 15480330
[TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
4. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study.
Caproni M; Torchia D; Antiga E; Terranova M; Volpi W; del Bianco E; D'Agata A; Fabbri P
Br J Dermatol; 2007 Feb; 156(2):312-9. PubMed ID: 17223872
[TBL] [Abstract][Full Text] [Related]
5. Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis.
Antúnez C; Torres MJ; Mayorga C; Cornejo-García JA; Santamaría-Babi LF; Blanca M
Clin Exp Allergy; 2004 Apr; 34(4):559-66. PubMed ID: 15080808
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
Schuller E; Oppel T; Bornhövd E; Wetzel S; Wollenberg A
J Allergy Clin Immunol; 2004 Jul; 114(1):137-43. PubMed ID: 15241357
[TBL] [Abstract][Full Text] [Related]
7. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
8. Epidermal caspase-3 cleavage associated with interferon-gamma-expressing lymphocytes in acute atopic dermatitis lesions.
Simon D; Lindberg RL; Kozlowski E; Braathen LR; Simon HU
Exp Dermatol; 2006 Jun; 15(6):441-6. PubMed ID: 16689860
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
12. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
14. Cytokine production, activation marker, and skin homing receptor in children with atopic dermatitis and bronchial asthma.
Antúnez C; Torres MJ; Mayorga C; Corzo JL; Jurado A; Santamaría-Babi LF; Vera A; Blanca M
Pediatr Allergy Immunol; 2006 May; 17(3):166-74. PubMed ID: 16672002
[TBL] [Abstract][Full Text] [Related]
15. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.
Kaufmann R; Bieber T; Helgesen AL; Andersen BL; Luger T; Poulin Y; Al-Hafidh J; Paul C;
Allergy; 2006 Mar; 61(3):375-81. PubMed ID: 16436149
[TBL] [Abstract][Full Text] [Related]
16. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
[TBL] [Abstract][Full Text] [Related]
17. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
18. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
[TBL] [Abstract][Full Text] [Related]
19. Mononuclear cells in atopic dermatitis in vivo: immunomodulation of the cutaneous infiltrate by medium-dose UVA1 phototherapy.
Breuckmann F; von Kobyletzki G; Avermaete A; Pieck C; Kreuter A; Brockmeyer NH; Altmeyer P; Gambichler T
Eur J Med Res; 2002 Jul; 7(7):315-22. PubMed ID: 12176681
[TBL] [Abstract][Full Text] [Related]
20. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
